New Class of Schizophrenic Drugs Unveiled

by VR Sreeraman on September 3, 2007 at 2:32 PM
New Class of Schizophrenic Drugs Unveiled

A new class of Schizophrenia drugs, that targets different molecule messengers in the brain, has been unveiled.

Getty psychiatrists have welcomed the drugs, which are the first since 1950.


Clinical trials show that the drugs codenamed LY2140023, produced by Eli Lilly researchers in Indianapolis, Indiana, are as effective as olanzapine, the best currently available drug.

Schizophrenia has a wide range of debilitating symptoms that includes delusions, hallucination, disordered thinking, social withdrawal and emotional 'flatness'.

Current anti-schizophrenia drugs operate in a similar way by cutting down levels of neurotransmitter dopamine in the brain.

However, the drugs do not control the condition in all people and lead to unpleasant side effects.

The new drug is changed in the body into a second compound, called LY404023, which acts by slowing down the activity of a different neurotransmitter, glutamate.

"Our study is the first conclusive evidence for a role of glutamate in the pathophysiology of schizophrenia," Nature quoted James Monn, one of the research team, as saying.

In the trial, 196 schizophrenic patients were administered with LY2140023, olanzapine or a placebo for four weeks. The drugs were roughly equally effective.

"In terms of drug development this is a giant step forward pretty much the first major step forward since 1952, when chlorpromazine was introduced," Solomon Snyder, a neuropharmacologist at Johns Hopkins University in Baltimore, Maryland said.

The side effects of LY2140023 did not cause weight gain like other current antipsychotic drugs.

Researchers observed the possibility that glutamate system might be involved in schizophrenia, when the drug party drug phencyclidine triggered a temporary psychosis alike to the disease.

Though Monn admits that it is unknown how the new drug causes its antipsychotic actions, it is bio chemically a subtly reaction and operates on on a particular glutamate receptor called mGlu2/3.

The receptor has a feedback loop that works only when the glutamate system is very active.

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Class of Schizophrenic Drugs Unveiled Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests